FIXX News and Press, Homology Medicines Inc. From 02/22/22

For the overall market, Tuesday's midday trading was dominated by continued concerns about Russia and Ukraine, which had the major averages sharply lower during the early afternoon. That said, some individual stocks managed to post notable gains, with Donald Trump, earnings and regulator deci...

Gainers: Indonesia (NYSE:INDO) +79%. Meritor (NYSE:MTOR) +45%. Ocugen (NASDAQ:OCGN) +22%. Datasea (NASDAQ:DTSS) +20%. IronNet (NYSE:IRNT) +20%. Riley Exploration Permian (NYSE:REPX) +19%. Arteris (NASDAQ:AIP) +17%. Houghton Mifflin Harcourt Company (NASDAQ:HMHC) +15%. MEDIROM Healthcare Techn...

Oppenheimer has downgraded Homology Medicines (FIXX -26.6%) to perform following the company's announcement on Friday that the U.S. Food and Drug Administration imposed a clinical hold on its pheNIX gene therapy trial of HMI-102 for phenylketonuria. Shares are down ~27%. The firm ha...

Gainers: HOOKIPA Pharma HOOK +18%. Nuvectis Pharma (NASDAQ:NVCT) +16%. Ocugen OCGN +14%. Privia Health (NASDAQ:PRVA) +12%. IMARA (NASDAQ:IMRA) +11%. Losers: Allarity Therapeutics (NASDAQ:ALLR) -29%. Homology Medicines FIXX -27%. Karyopharm The...

Homology Medicines (NASDAQ:FIXX) -25% on FDA clinical hold for phenylketonuria trial. Karyopharm Therapeutics (NASDAQ:KPTI) -23% as medical chief steps down. Inspirato (NASDAQ:ISPO) -17%. QIWI (NASDAQ:QIWI) -14%. Yandex (NASDAQ:YNDX) -13%. Energy Vault (NYSE:NRGV) -12%. Ar...

Homology Medicines (NASDAQ:FIXX) has lost ~35% in the post-market Friday after the genetic medicines company announced that the U.S. Food and Drug Administration (FDA) imposed a clinical hold on its pheNIX gene therapy trial of HMI-102 in adults with phenylketonuria (PKU). The need ...

BEDFORD, Mass., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that the U.S. Food and Drug Administration (FDA) has notified the company that its pheNIX gene therapy trial of HMI-102 in adults with phenylketonuria (PKU...

- Data Supported juMPStart Trial Evaluating One-Time, Systemic Administration of HMI-203 in ERT-Treated Adults - - Details of HMI-203 Clinical Trial Design and Encouraging Preclinical Data Featured in Platform Presentations - BEDFORD, Mass., Feb. 10, 2022 (...

Oxford Biomedica and Homology Medicines to establish Oxford Biomedica Solutions LLC, a new U.S.-based AAV Manufacturing and Innovation Business Homology Medicines to receive $130 million from Oxford Biomedica to continue to advance its three clinical programs and genetic medicin...

Homology Medicines (NASDAQ:FIXX): Q3 GAAP EPS of -$0.54 beats by $0.08. Revenue of $1.67M (+193.0% Y/Y) beats by $0.87M. Press Release For further details see: Homology Medicines EPS beats by $0.08, beats on revenue